{"nctId":"NCT01281202","briefTitle":"Vigabatrin for the Treatment of Cocaine Dependency","startDateStruct":{"date":"2011-01"},"conditions":["Cocaine Addiction","Cocaine Dependence"],"count":207,"armGroups":[{"label":"CPP-109 Vigabatrin Tablets","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vigabatrin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching Placebo"]}],"interventions":[{"name":"Vigabatrin","otherNames":["CPP-109","GVG","VGB"]},{"name":"Matching Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Able to understand the study and provide written informed consent.\n* Male or female at least 18 years of age.\n* Meet DSM-IV criteria for cocaine dependence as primary diagnosis, as determined by the Substance Abuse Structured Clinical Interview (SCID) for Diagnostic and Statistical Manual-IV (DSM-IV) module.\n* Have a verifiable place of primary residence.\n* Seeking treatment for cocaine dependence.\n* Be in generally good health based on history, physical examination, electrocardiogram, eye exam and laboratory findings.\n* If female of childbearing potential, use acceptable contraceptive methods (oral contraceptives (the pill), intrauterine device (IUD), contraceptive implants under the skin, contraceptive rings or patches or injections, diaphragms with spermicide, and condoms with spermicide). Surgical sterilization by tubal ligation or hysterectomy is acceptable.\n\nExclusion Criteria:\n\n* Please contact site for more information","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Abstinence","description":"The number of subjects in each treatment group who are cocaine abstinent during the last 2 weeks of the Treatment Phase (Weeks 8 and 9).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Cocaine Use","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":103},"commonTop":["Headache","Nausea","Fatigue","Back pain","Pain in extremity"]}}}